Tamiflu Oseltamivir Phosphate Market Size 2025-2029
The tamiflu oseltamivir phosphate market size is forecast to increase by USD 204.5 million, at a CAGR of 4.6% between 2024 and 2029.
The global tamiflu oseltamivir phosphate market is primarily driven by the annual incidence and severity of seasonal influenza. This creates a direct correlation between epidemiological trends and demand, where factors like circulating viral strains and vaccine effectiveness dictate consumption volumes. Public health surveillance is crucial for informing clinical decisions and managing supply chains. This dynamic is occurring alongside a broader evolution in the phosphate market, where specialized applications are gaining prominence. The development of new drug delivery systems further highlights the industry's focus on improving therapeutic outcomes, with research into advanced formulations shaping future treatment paradigms and presenting opportunities for differentiation in a mature market.A gradual shift toward novel antiviral therapies with alternative mechanisms of action is reshaping the competitive landscape. These newer agents offer improved dosing regimens, appealing to both clinicians and patients who prioritize convenience. However, this trend coincides with the market's foremost challenge: intense generic competition that leads to significant price erosion. This pressure has commoditized oseltamivir, particularly its generic forms, forcing manufacturers to compete almost entirely on price. The use of rnai drug delivery market technologies in other therapeutic areas is indicative of the innovation that oseltamivir must now compete against, solidifying its position as a cost-effective workhorse in a diversifying treatment ecosystem.
What will be the Size of the Tamiflu Oseltamivir Phosphate Market during the forecast period?
Explore in-depth regional segment analysis with market size data - historical 2019 - 2023 and forecasts 2025-2029 - in the full report.
Request Free Sample
The market is characterized by the ongoing refinement of antiviral therapy protocols and the strategic management of pediatric dosing requirements. The availability of oral suspension formulations remains a critical aspect of market offerings, ensuring that therapeutic equivalence is maintained across different patient populations, including those unable to take solid dosage forms. Evolving clinical treatment guidelines continuously shape prescribing habits, influencing the balance between established and novel therapeutic agents.Supply chain diversification is emerging as a important strategic focus, compelling manufacturers to re-evaluate their global production footprints to ensure supply continuity. This shift is closely tied to cost containment measures, as companies seek to balance operational resilience with pricing pressures in a competitive landscape. This dynamic is further influenced by the increasing integration of telehealth platforms, which are altering how patients access care and receive prescriptions.The market is also shaped by innovations in related fields, including the pharmaceutical isolator market, which enhances manufacturing safety and efficiency. Advances in point-of-care diagnostics are enabling more precise and timely administration of treatments, optimizing patient outcomes. Concurrently, the rise of pharmaceutical innovation in areas like the rnai drug delivery market is creating new benchmarks for convenience and efficacy, against which established therapies are increasingly measured.
How is this Tamiflu Oseltamivir Phosphate Industry segmented?
The tamiflu oseltamivir phosphate industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2025-2029, as well as historical data from 2019 - 2023 for the following segments.
- Type
- Formulation
- Indication
- Influenza A
- Influenza B
- Swine flu
- Geography
- Asia
- North America
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Russia
- The Netherlands
- Rest of World (ROW)
By Type Insights
The branded segment is estimated to witness significant growth during the forecast period.
The branded segment is defined by the originator product, which established the standard of care through extensive clinical trials and a formidable global marketing network. This created a high degree of trust and brand recognition among healthcare professionals. Following the loss of market exclusivity, its strategy shifted to value retention, maintaining a premium price point. This approach targets specific niches where brand loyalty persists or where procurement criteria favor the originator's established supply chain and long-term stability data.
This segment faces the unrelenting challenge of generic erosion, with low-cost alternatives systematically capturing the majority of market volume. Despite this, the branded segment retains a significant market share, accounting for approximately 60% of the total market value in recent periods, primarily due to legacy brand loyalty in certain markets. Consequently, its revenue trajectory is now intrinsically linked to the severity of seasonal influenza and its ability to defend a diminishing share against a backdrop of commoditization.
Request Free Sample
The Branded segment was valued at USD 445.10 million in 2019 and showed a gradual increase during the forecast period.
Regional Analysis
Asia is estimated to contribute 45.6% to the growth of the global market during the forecast period.Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
Request Free Sample
The market in Asia is globally significant, characterized by a sharp contrast between highly developed healthcare systems and rapidly emerging economies. In nations like Japan, the market is mature, with high per-capita consumption and robust government stockpiling programs. This creates a stable, high-volume demand environment driven by established clinical practices. Conversely, emerging countries like China and India are defined by their immense scale, serving as both vast consumer markets and central hubs for global generic manufacturing, which underpins the worldwide supply of affordable oseltamivir.
Representing over 45% of the global market opportunity, Asia's growth is fueled by improving healthcare infrastructure, rising incomes, and government initiatives to strengthen public health and pandemic preparedness. The region's dual role as a primary producer and a major consumer of low-cost generics drives both domestic use and exports. The persistent threat of zoonotic influenza originating in the region acts as a powerful and continuous catalyst for both seasonal demand and strategic government procurement, making Asia a focal point for the market's future trajectory.
Market Dynamics
Our researchers analyzed the data with 2024 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The global Tamiflu Oseltamivir Phosphate market's trajectory is heavily influenced by the seasonal influenza incidence and severity, with demand closely tracking the annual incidence and clinical severity of seasonal influenza. A significant driver remains government stockpiling and pandemic preparedness policies, which are integral to national and international pandemic preparedness strategies, leveraging the drug's broad spectrum activity against influenza a viruses. However, the market is characterized by the widespread availability of generic formulations. This has led to intense generic competition and severe price erosion, creating a landscape of pervasive and intense competition among generic manufacturers. The proliferation of generic tamiflu oseltamivir phosphate underscores the market's commoditization, even as the cost effectiveness of generic oseltamivir sustains its relevance in public health arsenals.Market participants face significant headwinds, including the increasing adoption of novel antiviral therapies and a gradual shift towards newer antiviral agents. Compounding this is the high threat from substitute products and preventative measures, such as vaccines and other preventative public health interventions and alternative medications. This environment contributes to demand volatility and complex supply chain management, leading to unpredictability in forecasting and production planning. In response, leading firms are pursuing strategic diversification of manufacturing footprints and the geographic diversification of manufacturing operations to mitigate risks. Furthermore, the integration of digital health and advanced diagnostics and the progressive integration of digital health technologies are emerging as key strategies to improve forecasting accuracy and manage market dynamics more effectively.
What are the key market drivers leading to the rise in the adoption of Tamiflu Oseltamivir Phosphate Industry?
- The annual incidence and clinical severity of seasonal influenza is the most significant and immediate driver for the global tamiflu oseltamivir phosphate market.
The most immediate driver for the tamiflu oseltamivir phosphate market is the direct, real-time reflection of seasonal epidemiological trends. Demand exhibits a pronounced cyclicality, surging during winter months in correlation with influenza virus activity. The magnitude of this surge is proportional to the virulence of circulating strains and the effectiveness of the seasonal vaccine. Public health surveillance provides critical data that informs clinical decision-making, creating a highly responsive demand environment where high flu activity prompts increased testing and empirical antiviral therapy. With undifferentiated purchases having a high impact on the market, nearly 90% of buyers prioritize price, which shapes competitive dynamics significantly. This link between public health data and clinical practice is central to the market's performance.A foundational long-term driver is the central role of oseltamivir in pandemic preparedness strategies. This driver operates independently of seasonal demand and is rooted in the public health imperative to mitigate the impact of a future influenza pandemic. It is characterized by large, infrequent, high-volume procurement contracts from government agencies for strategic national stockpiles. Demand from this segment creates a stable, albeit lumpy, baseline of demand, providing a degree of predictability for manufacturers. The availability of cost-effective generic oseltamivir is a critical enabler, allowing governments worldwide to build and maintain substantial stockpiles, reinforcing the drug's indispensable role as a medical countermeasure.
What are the market trends shaping the Tamiflu Oseltamivir Phosphate Industry?
- An evolving trend in the global influenza treatment landscape is the increasing adoption of novel antiviral therapies with alternative mechanisms of action.
A transformative trend in the influenza treatment landscape is the steady clinical shift toward newer antiviral agents with alternative mechanisms of action. The introduction of drug classes like endonuclease inhibitors presents therapeutic alternatives offering distinct advantages, most notably single oral-dose regimens. This convenience significantly improves patient adherence compared to oseltamivir's five-day course. This trend is creating a stratified market where novel, on-patent agents capture the premium segment, particularly in developed economies. Despite this shift, legacy branded products still represent a significant portion of market value, accounting for over 60% in recent years, highlighting a gradual transition. This repositions generic oseltamivir as the reliable, cost-effective, high-volume standard, especially for large-scale government stockpiles where the phosphate esters market cost is paramount.A critical operational trend shaping the market is the strategic geographic diversification of manufacturing. The industry is moving away from concentrating production in a few low-cost regions to building more robust and dispersed manufacturing networks. This shift from pure cost optimization to supply chain resilience is driven by a need to de-risk production from regional disruptions like geopolitical instability or natural disasters. For the market's largest purchasers, especially government agencies, a manufacturer's diversified production footprint is now a key criterion and a significant competitive differentiator. This trend, similar to risk mitigation in the calcium-zinc stabilizer market, is altering procurement calculus, where demonstrating operational resilience can justify a price premium and secure strategic partnerships.
What challenges does the Tamiflu Oseltamivir Phosphate Industry face during its growth?
- A paramount challenge confronting the global tamiflu oseltamivir phosphate market is the intense competition among generic manufacturers, leading to severe price erosion.
A defining challenge for the global tamiflu oseltamivir phosphate market is the intense and pervasive competition among generic manufacturers, which has led to severe and sustained price erosion. Following the loss of market exclusivity for the originator product, a multitude of suppliers entered the market, transforming oseltamivir into a commodity where price became the primary basis of competition. This dynamic has granted immense bargaining power to large-scale purchasers, such as government health ministries and hospital group purchasing organizations. These entities leverage the hyper-competitive environment to drive prices down to marginal cost levels. The market is characterized by this intense price competition, with over 85% of procurement decisions in the generic segment being primarily price-driven, severely compressing profit margins for all participants.The market's long-term growth potential is fundamentally challenged by a high and increasing threat from substitutes, which exist in two primary forms. The most significant is preventative measures, particularly influenza vaccines. Successful vaccination campaigns that improve immunogenicity and increase coverage rates directly reduce the addressable patient population for therapeutic antiviral drugs. The second threat comes from direct therapeutic competition from newer classes of antiviral drugs. These next-generation products, such as endonuclease inhibitors, often present a more compelling clinical value proposition, most notably through more convenient single-dose administration. As these innovative drugs become established in treatment guidelines, oseltamivir risks being relegated to a second-line or lower-cost alternative, capping its market potential.
Exclusive Customer Landscape
The tamiflu oseltamivir phosphate market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the tamiflu oseltamivir phosphate market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Key Companies & Market Insights
Companies are implementing various strategies, such as strategic alliances, tamiflu oseltamivir phosphate market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the industry.
Alembic Pharmaceuticals Ltd. - The offering comprises branded capsules and suspension formulations of the antiviral agent, supported by extensive global clinical validation establishing its efficacy and safety profile. This portfolio is strategically positioned to serve markets where brand recognition and a long-standing history of clinical use remain key considerations for healthcare providers and in specific procurement contracts that prioritize originator product data.
The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
- Alembic Pharmaceuticals Ltd.
- Amneal Pharmaceuticals Inc.
- Aurobindo Pharma Ltd.
- Cipla Inc.
- Epic Pharma LLC
- F. Hoffmann La Roche Ltd.
- Gilead Sciences Inc.
- Hetero Labs Ltd.
- Jubilant Generics Ltd.
- Laurus Labs Ltd.
- Lupin Ltd.
- Macleods Pharmaceuticals Ltd.
- MSN Laboratories
- NATCO Pharma Ltd.
- Nivagen Pharmaceuticals Inc.
- Strides Pharma Ltd.
- Teva Pharmaceutical Ltd.
- Viatris Inc.
- Zydus Group
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Recent Development and News in Tamiflu Oseltamivir Phosphate Market
In May 2024, the US Administration for Strategic Preparedness and Response (ASPR) highlighted the critical role of its antiviral reserves in its national health security posture. Following the detection of the HPAI A(H5N1) virus in dairy cattle and a related human case, the agency publicly affirmed that it was closely monitoring its extensive stockpile of oseltamivir as part of its comprehensive pandemic readiness efforts.In April 2024, F. Hoffmann-La Roche Ltd. and Shionogi announced positive top-line results from a Phase III clinical trial for a competing agent, baloxavir marboxil, in hospitalized patients with severe influenza. The success of this next-generation therapy in a critical patient population indicates a potential future shift in treatment paradigms, signaling intensifying competition for oseltamivir in high-acuity care settings.In March 2024, Teva Pharmaceutical Industries Ltd. noted in its annual report filing a consistent demand for its generic oseltamivir phosphate product, particularly in connection with the seasonal influenza period. The company emphasized its operational readiness and role as a reliable supplier, demonstrating how major generic players have integrated the production of essential medicines like oseltamivir into their core operations to consistently meet predictable seasonal demand and ensure broad, affordable access.
Research Analyst Overview
The global tamiflu oseltamivir phosphate market is fundamentally shaped by its role as a key neuraminidase inhibitor within the broader class of antiviral medication. Its primary application against influenza a and b viruses positions it at the center of pandemic preparedness strategies and government stockpiling programs. The management of the strategic national stockpile (SNS) is directly responsive to shifts in public health surveillance data, including epidemiological trends related to seasonal influenza incidence and the perceived zoonotic influenza threat. Continuous monitoring for antigenic drift and shift is critical, as these viral changes can impact the effectiveness of treatments that target neuraminidase activity to inhibit viral replication. The emergence of antiviral resistance remains a persistent concern that informs ongoing surveillance and treatment protocols, representing a dynamic variable for public health planning.Market dynamics are increasingly defined by intense generic competition, leading to significant price erosion and a focus on cost containment measures. The development of generic formulations, including both oseltamivir phosphate capsules and the oral suspension formulation, requires demonstration of therapeutic equivalence through rigorous bioanalytical testing to create bioequivalent formulations. This competitive landscape affects supply chain management and procurement contracts, with the sector anticipating a value expansion of nearly 4%. Manufacturing efficiency in producing the active pharmaceutical ingredient (API) and managing outbound logistics is crucial for navigating demand volatility. Furthermore, pharmaceutical innovation continues with drug discovery and preclinical trials for novel agents like endonuclease inhibitors. Adoption is guided by clinical treatment guidelines, while service delivery evolves with telehealth integration and point-of-care diagnostics to improve patient adherence. Reimbursement frameworks and shelf life management remain pivotal operational considerations for stakeholders.
Dive into Technavio’s robust research methodology, blending expert interviews, extensive data synthesis, and validated models for unparalleled Tamiflu Oseltamivir Phosphate Market insights. See full methodology.
|
Market Scope
|
|
Report Coverage
|
Details
|
|
Page number
|
285
|
|
Base year
|
2024
|
|
Historic period
|
2019 - 2023 |
|
Forecast period
|
2025-2029
|
|
Growth momentum & CAGR
|
Accelerating at a CAGR of 4.6%
|
|
Market growth 2024-2029
|
USD 204.5 million
|
|
Market structure
|
Fragmented
|
|
YoY growth 2024-2029(%)
|
4.4%
|
|
Key countries
|
China, Japan, India, South Korea, Indonesia, Singapore, Thailand, US, Canada, Mexico, Germany, France, UK, Italy, Spain, Russia, The Netherlands, Brazil, South Africa, Saudi Arabia, UAE, Australia, Turkey
|
|
Competitive landscape
|
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks
|
Request Free Sample
What are the Key Data Covered in this Tamiflu Oseltamivir Phosphate Market Research and Growth Report?
- CAGR of the Tamiflu Oseltamivir Phosphate industry during the forecast period
- Detailed information on factors that will drive the growth and forecasting between 2024 and 2029
- Precise estimation of the size of the market and its contribution of the industry in focus to the parent market
- Accurate predictions about upcoming growth and trends and changes in consumer behaviour
- Growth of the market across Asia, North America, Europe, Rest of World (ROW)
- Thorough analysis of the market’s competitive landscape and detailed information about companies
- Comprehensive analysis of factors that will challenge the tamiflu oseltamivir phosphate market growth of industry companies
We can help! Our analysts can customize this tamiflu oseltamivir phosphate market research report to meet your requirements.
Get in touch
1 Executive Summary
- 1 Executive Summary
- 1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Global Market Characteristics
- Executive Summary - Chart on Market by Geography
- Executive Summary - Chart on Market Segmentation by Type
- Executive Summary - Chart on Market Segmentation by Formulation
- Executive Summary - Chart on Market Segmentation by Indication
- Executive Summary - Chart on Incremental Growth
- Executive Summary - Data Table on Incremental Growth
- Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis
- 2 Technavio Analysis
- 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- 2.2 Criticality of inputs and Factors of differentiation
- Chart on Overview on criticality of inputs and factors of differentiation
- 2.3 Factors of disruption
- Chart on Overview on factors of disruption
- 2.4 Impact of drivers and challenges
- Chart on Impact of drivers and challenges in 2024 and 2029
3 Market Landscape
- 3 Market Landscape
- 3.1 Market ecosystem
- Chart on Parent Market
- Data Table on - Parent Market
- 3.2 Market characteristics
- Chart on Market characteristics analysis
- 3.3 Value chain analysis
- Chart on Value chain analysis
4 Market Sizing
- 4 Market Sizing
- 4.1 Market definition
- Data Table on Offerings of companies included in the market definition
- 4.2 Market segment analysis
- 4.3 Market size 2024
- 4.4 Market outlook: Forecast for 2024-2029
- Chart on Global - Market size and forecast 2024-2029 ($ billion)
- Data Table on Global - Market size and forecast 2024-2029 ($ billion)
- Chart on Global Market: Year-over-year growth 2024-2029 (%)
- Data Table on Global Market: Year-over-year growth 2024-2029 (%)
5 Historic Market Size
- 5 Historic Market Size
- 5.1 Global Tamiflu Oseltamivir Phosphate Market 2019 - 2023
- Historic Market Size - Data Table on Global Tamiflu Oseltamivir Phosphate Market 2019 - 2023 ($ billion)
- 5.2 Type segment analysis 2019 - 2023
- Historic Market Size - Type Segment 2019 - 2023 ($ billion)
- 5.3 Formulation segment analysis 2019 - 2023
- Historic Market Size - Formulation Segment 2019 - 2023 ($ billion)
- 5.4 Indication segment analysis 2019 - 2023
- Historic Market Size - Indication Segment 2019 - 2023 ($ billion)
- 5.5 Geography segment analysis 2019 - 2023
- Historic Market Size - Geography Segment 2019 - 2023 ($ billion)
- 5.6 Country segment analysis 2019 - 2023
- Historic Market Size - Country Segment 2019 - 2023 ($ billion)
6 Qualitative Analysis
- 6 Qualitative Analysis
- 6.1 The AI impact on global tamiflu oseltamivir phosphate market
7 Five Forces Analysis
- 7 Five Forces Analysis
- 7.1 Five forces summary
- Five forces analysis - Comparison between 2024 and 2029
- 7.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2024 and 2029
- 7.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2024 and 2029
- 7.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2024 and 2029
- 7.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2024 and 2029
- 7.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2024 and 2029
- 7.7 Market condition
- Chart on Market condition - Five forces 2024 and 2029
8 Market Segmentation by Type
- 8 Market Segmentation by Type
- 8.1 Market segments
- Chart on Type - Market share 2024-2029 (%)
- Data Table on Type - Market share 2024-2029 (%)
- 8.2 Comparison by Type
- Chart on Comparison by Type
- Data Table on Comparison by Type
- 8.3 Branded - Market size and forecast 2024-2029
- Chart on Branded - Market size and forecast 2024-2029 ($ billion)
- Data Table on Branded - Market size and forecast 2024-2029 ($ billion)
- Chart on Branded - Year-over-year growth 2024-2029 (%)
- Data Table on Branded - Year-over-year growth 2024-2029 (%)
- 8.4 Generic - Market size and forecast 2024-2029
- Chart on Generic - Market size and forecast 2024-2029 ($ billion)
- Data Table on Generic - Market size and forecast 2024-2029 ($ billion)
- Chart on Generic - Year-over-year growth 2024-2029 (%)
- Data Table on Generic - Year-over-year growth 2024-2029 (%)
- 8.5 Market opportunity by Type
- Market opportunity by Type ($ billion)
- Data Table on Market opportunity by Type ($ billion)
9 Market Segmentation by Formulation
- 9 Market Segmentation by Formulation
- 9.1 Market segments
- Chart on Formulation - Market share 2024-2029 (%)
- Data Table on Formulation - Market share 2024-2029 (%)
- 9.2 Comparison by Formulation
- Chart on Comparison by Formulation
- Data Table on Comparison by Formulation
- 9.3 Capsules - Market size and forecast 2024-2029
- Chart on Capsules - Market size and forecast 2024-2029 ($ billion)
- Data Table on Capsules - Market size and forecast 2024-2029 ($ billion)
- Chart on Capsules - Year-over-year growth 2024-2029 (%)
- Data Table on Capsules - Year-over-year growth 2024-2029 (%)
- 9.4 Suspension - Market size and forecast 2024-2029
- Chart on Suspension - Market size and forecast 2024-2029 ($ billion)
- Data Table on Suspension - Market size and forecast 2024-2029 ($ billion)
- Chart on Suspension - Year-over-year growth 2024-2029 (%)
- Data Table on Suspension - Year-over-year growth 2024-2029 (%)
- 9.5 Market opportunity by Formulation
- Market opportunity by Formulation ($ billion)
- Data Table on Market opportunity by Formulation ($ billion)
10 Market Segmentation by Indication
- 10 Market Segmentation by Indication
- 10.1 Market segments
- Chart on Indication - Market share 2024-2029 (%)
- Data Table on Indication - Market share 2024-2029 (%)
- 10.2 Comparison by Indication
- Chart on Comparison by Indication
- Data Table on Comparison by Indication
- 10.3 Influenza A - Market size and forecast 2024-2029
- Chart on Influenza A - Market size and forecast 2024-2029 ($ billion)
- Data Table on Influenza A - Market size and forecast 2024-2029 ($ billion)
- Chart on Influenza A - Year-over-year growth 2024-2029 (%)
- Data Table on Influenza A - Year-over-year growth 2024-2029 (%)
- 10.4 Influenza B - Market size and forecast 2024-2029
- Chart on Influenza B - Market size and forecast 2024-2029 ($ billion)
- Data Table on Influenza B - Market size and forecast 2024-2029 ($ billion)
- Chart on Influenza B - Year-over-year growth 2024-2029 (%)
- Data Table on Influenza B - Year-over-year growth 2024-2029 (%)
- 10.5 Swine flu - Market size and forecast 2024-2029
- Chart on Swine flu - Market size and forecast 2024-2029 ($ billion)
- Data Table on Swine flu - Market size and forecast 2024-2029 ($ billion)
- Chart on Swine flu - Year-over-year growth 2024-2029 (%)
- Data Table on Swine flu - Year-over-year growth 2024-2029 (%)
- 10.6 Market opportunity by Indication
- Market opportunity by Indication ($ billion)
- Data Table on Market opportunity by Indication ($ billion)
11 Customer Landscape
- 11 Customer Landscape
- 11.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
12 Geographic Landscape
- 12 Geographic Landscape
- 12.1 Geographic segmentation
- Chart on Market share by geography 2024-2029 (%)
- Data Table on Market share by geography 2024-2029 (%)
- 12.2 Geographic comparison
- Chart on Geographic comparison
- Data Table on Geographic comparison
- 12.3 Asia - Market size and forecast 2024-2029
- Chart on Asia - Market size and forecast 2024-2029 ($ billion)
- Data Table on Asia - Market size and forecast 2024-2029 ($ billion)
- Chart on Asia - Year-over-year growth 2024-2029 (%)
- Data Table on Asia - Year-over-year growth 2024-2029 (%)
- Chart on Regional Comparison - Asia
- Data Table on Regional Comparison - Asia
- 12.3.1 China - Market size and forecast 2024-2029
- Chart on China - Market size and forecast 2024-2029 ($ billion)
- Data Table on China - Market size and forecast 2024-2029 ($ billion)
- Chart on China - Year-over-year growth 2024-2029 (%)
- Data Table on China - Year-over-year growth 2024-2029 (%)
- 12.3.2 Japan - Market size and forecast 2024-2029
- Chart on Japan - Market size and forecast 2024-2029 ($ billion)
- Data Table on Japan - Market size and forecast 2024-2029 ($ billion)
- Chart on Japan - Year-over-year growth 2024-2029 (%)
- Data Table on Japan - Year-over-year growth 2024-2029 (%)
- 12.3.3 India - Market size and forecast 2024-2029
- Chart on India - Market size and forecast 2024-2029 ($ billion)
- Data Table on India - Market size and forecast 2024-2029 ($ billion)
- Chart on India - Year-over-year growth 2024-2029 (%)
- Data Table on India - Year-over-year growth 2024-2029 (%)
- 12.3.4 South Korea - Market size and forecast 2024-2029
- Chart on South Korea - Market size and forecast 2024-2029 ($ billion)
- Data Table on South Korea - Market size and forecast 2024-2029 ($ billion)
- Chart on South Korea - Year-over-year growth 2024-2029 (%)
- Data Table on South Korea - Year-over-year growth 2024-2029 (%)
- 12.3.5 Indonesia - Market size and forecast 2024-2029
- Chart on Indonesia - Market size and forecast 2024-2029 ($ billion)
- Data Table on Indonesia - Market size and forecast 2024-2029 ($ billion)
- Chart on Indonesia - Year-over-year growth 2024-2029 (%)
- Data Table on Indonesia - Year-over-year growth 2024-2029 (%)
- 12.3.6 Singapore - Market size and forecast 2024-2029
- Chart on Singapore - Market size and forecast 2024-2029 ($ billion)
- Data Table on Singapore - Market size and forecast 2024-2029 ($ billion)
- Chart on Singapore - Year-over-year growth 2024-2029 (%)
- Data Table on Singapore - Year-over-year growth 2024-2029 (%)
- 12.3.7 Thailand - Market size and forecast 2024-2029
- Chart on Thailand - Market size and forecast 2024-2029 ($ billion)
- Data Table on Thailand - Market size and forecast 2024-2029 ($ billion)
- Chart on Thailand - Year-over-year growth 2024-2029 (%)
- Data Table on Thailand - Year-over-year growth 2024-2029 (%)
- 12.4 North America - Market size and forecast 2024-2029
- Chart on North America - Market size and forecast 2024-2029 ($ billion)
- Data Table on North America - Market size and forecast 2024-2029 ($ billion)
- Chart on North America - Year-over-year growth 2024-2029 (%)
- Data Table on North America - Year-over-year growth 2024-2029 (%)
- Chart on Regional Comparison - North America
- Data Table on Regional Comparison - North America
- 12.4.1 US - Market size and forecast 2024-2029
- Chart on US - Market size and forecast 2024-2029 ($ billion)
- Data Table on US - Market size and forecast 2024-2029 ($ billion)
- Chart on US - Year-over-year growth 2024-2029 (%)
- Data Table on US - Year-over-year growth 2024-2029 (%)
- 12.4.2 Canada - Market size and forecast 2024-2029
- Chart on Canada - Market size and forecast 2024-2029 ($ billion)
- Data Table on Canada - Market size and forecast 2024-2029 ($ billion)
- Chart on Canada - Year-over-year growth 2024-2029 (%)
- Data Table on Canada - Year-over-year growth 2024-2029 (%)
- 12.4.3 Mexico - Market size and forecast 2024-2029
- Chart on Mexico - Market size and forecast 2024-2029 ($ billion)
- Data Table on Mexico - Market size and forecast 2024-2029 ($ billion)
- Chart on Mexico - Year-over-year growth 2024-2029 (%)
- Data Table on Mexico - Year-over-year growth 2024-2029 (%)
- 12.5 Europe - Market size and forecast 2024-2029
- Chart on Europe - Market size and forecast 2024-2029 ($ billion)
- Data Table on Europe - Market size and forecast 2024-2029 ($ billion)
- Chart on Europe - Year-over-year growth 2024-2029 (%)
- Data Table on Europe - Year-over-year growth 2024-2029 (%)
- Chart on Regional Comparison - Europe
- Data Table on Regional Comparison - Europe
- 12.5.1 Germany - Market size and forecast 2024-2029
- Chart on Germany - Market size and forecast 2024-2029 ($ billion)
- Data Table on Germany - Market size and forecast 2024-2029 ($ billion)
- Chart on Germany - Year-over-year growth 2024-2029 (%)
- Data Table on Germany - Year-over-year growth 2024-2029 (%)
- 12.5.2 France - Market size and forecast 2024-2029
- Chart on France - Market size and forecast 2024-2029 ($ billion)
- Data Table on France - Market size and forecast 2024-2029 ($ billion)
- Chart on France - Year-over-year growth 2024-2029 (%)
- Data Table on France - Year-over-year growth 2024-2029 (%)
- 12.5.3 UK - Market size and forecast 2024-2029
- Chart on UK - Market size and forecast 2024-2029 ($ billion)
- Data Table on UK - Market size and forecast 2024-2029 ($ billion)
- Chart on UK - Year-over-year growth 2024-2029 (%)
- Data Table on UK - Year-over-year growth 2024-2029 (%)
- 12.5.4 Italy - Market size and forecast 2024-2029
- Chart on Italy - Market size and forecast 2024-2029 ($ billion)
- Data Table on Italy - Market size and forecast 2024-2029 ($ billion)
- Chart on Italy - Year-over-year growth 2024-2029 (%)
- Data Table on Italy - Year-over-year growth 2024-2029 (%)
- 12.5.5 Spain - Market size and forecast 2024-2029
- Chart on Spain - Market size and forecast 2024-2029 ($ billion)
- Data Table on Spain - Market size and forecast 2024-2029 ($ billion)
- Chart on Spain - Year-over-year growth 2024-2029 (%)
- Data Table on Spain - Year-over-year growth 2024-2029 (%)
- 12.5.6 Russia - Market size and forecast 2024-2029
- Chart on Russia - Market size and forecast 2024-2029 ($ billion)
- Data Table on Russia - Market size and forecast 2024-2029 ($ billion)
- Chart on Russia - Year-over-year growth 2024-2029 (%)
- Data Table on Russia - Year-over-year growth 2024-2029 (%)
- 12.5.7 The Netherlands - Market size and forecast 2024-2029
- Chart on The Netherlands - Market size and forecast 2024-2029 ($ billion)
- Data Table on The Netherlands - Market size and forecast 2024-2029 ($ billion)
- Chart on The Netherlands - Year-over-year growth 2024-2029 (%)
- Data Table on The Netherlands - Year-over-year growth 2024-2029 (%)
- 12.6 Rest of World (ROW) - Market size and forecast 2024-2029
- Chart on Rest of World (ROW) - Market size and forecast 2024-2029 ($ billion)
- Data Table on Rest of World (ROW) - Market size and forecast 2024-2029 ($ billion)
- Chart on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
- Data Table on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
- Chart on Regional Comparison - Rest of World (ROW)
- Data Table on Regional Comparison - Rest of World (ROW)
- 12.6.1 Brazil - Market size and forecast 2024-2029
- Chart on Brazil - Market size and forecast 2024-2029 ($ billion)
- Data Table on Brazil - Market size and forecast 2024-2029 ($ billion)
- Chart on Brazil - Year-over-year growth 2024-2029 (%)
- Data Table on Brazil - Year-over-year growth 2024-2029 (%)
- 12.6.2 South Africa - Market size and forecast 2024-2029
- Chart on South Africa - Market size and forecast 2024-2029 ($ billion)
- Data Table on South Africa - Market size and forecast 2024-2029 ($ billion)
- Chart on South Africa - Year-over-year growth 2024-2029 (%)
- Data Table on South Africa - Year-over-year growth 2024-2029 (%)
- 12.6.3 Saudi Arabia - Market size and forecast 2024-2029
- Chart on Saudi Arabia - Market size and forecast 2024-2029 ($ billion)
- Data Table on Saudi Arabia - Market size and forecast 2024-2029 ($ billion)
- Chart on Saudi Arabia - Year-over-year growth 2024-2029 (%)
- Data Table on Saudi Arabia - Year-over-year growth 2024-2029 (%)
- 12.6.4 UAE - Market size and forecast 2024-2029
- Chart on UAE - Market size and forecast 2024-2029 ($ billion)
- Data Table on UAE - Market size and forecast 2024-2029 ($ billion)
- Chart on UAE - Year-over-year growth 2024-2029 (%)
- Data Table on UAE - Year-over-year growth 2024-2029 (%)
- 12.6.5 Australia - Market size and forecast 2024-2029
- Chart on Australia - Market size and forecast 2024-2029 ($ billion)
- Data Table on Australia - Market size and forecast 2024-2029 ($ billion)
- Chart on Australia - Year-over-year growth 2024-2029 (%)
- Data Table on Australia - Year-over-year growth 2024-2029 (%)
- 12.6.6 Turkey - Market size and forecast 2024-2029
- Chart on Turkey - Market size and forecast 2024-2029 ($ billion)
- Data Table on Turkey - Market size and forecast 2024-2029 ($ billion)
- Chart on Turkey - Year-over-year growth 2024-2029 (%)
- Data Table on Turkey - Year-over-year growth 2024-2029 (%)
- 12.7 Market opportunity by geography
- Market opportunity by geography ($ billion)
- Data Tables on Market opportunity by geography ($ billion)
13 Drivers, Challenges, and Opportunity
- 13 Drivers, Challenges, and Opportunity
- 13.1 Market drivers
- Seasonal influenza incidence and severity
- Government stockpiling and pandemic preparedness policies
- Widespread availability and affordability of generic formulations
- 13.2 Market challenges
- Intense generic competition and severe price erosion
- High threat from substitute products and preventative measures
- Demand volatility and complex supply chain management
- 13.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2024 and 2029
- 13.4 Market opportunities
- Increasing adoption of novel antiviral therapies
- Strategic diversification of manufacturing footprints
- Integration of digital health and advanced diagnostics in clinical pathways
14 Competitive Landscape
- 14 Competitive Landscape
- 14.1 Overview
- 14.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
- 14.3 Landscape disruption
- Overview on factors of disruption
- 14.4 Industry risks
- Impact of key risks on business
15 Competitive Analysis
- 15 Competitive Analysis
- 15.1 Companies profiled
- 15.2 Company ranking index
- 15.3 Market positioning of companies
- Matrix on companies position and classification
- 15.4 Alembic Pharmaceuticals Ltd.
- Alembic Pharmaceuticals Ltd. - Overview
- Alembic Pharmaceuticals Ltd. - Product / Service
- Alembic Pharmaceuticals Ltd. - Key offerings
- SWOT
- 15.5 Amneal Pharmaceuticals Inc.
- Amneal Pharmaceuticals Inc. - Overview
- Amneal Pharmaceuticals Inc. - Business segments
- Amneal Pharmaceuticals Inc. - Key news
- Amneal Pharmaceuticals Inc. - Key offerings
- Amneal Pharmaceuticals Inc. - Segment focus
- SWOT
- 15.6 Aurobindo Pharma Ltd.
- Aurobindo Pharma Ltd. - Overview
- Aurobindo Pharma Ltd. - Product / Service
- Aurobindo Pharma Ltd. - Key offerings
- SWOT
- 15.7 Cipla Inc.
- Cipla Inc. - Overview
- Cipla Inc. - Business segments
- Cipla Inc. - Key news
- Cipla Inc. - Key offerings
- Cipla Inc. - Segment focus
- SWOT
- 15.8 F. Hoffmann La Roche Ltd.
- F. Hoffmann La Roche Ltd. - Overview
- F. Hoffmann La Roche Ltd. - Business segments
- F. Hoffmann La Roche Ltd. - Key news
- F. Hoffmann La Roche Ltd. - Key offerings
- F. Hoffmann La Roche Ltd. - Segment focus
- SWOT
- 15.9 Gilead Sciences Inc.
- Gilead Sciences Inc. - Overview
- Gilead Sciences Inc. - Product / Service
- Gilead Sciences Inc. - Key news
- Gilead Sciences Inc. - Key offerings
- SWOT
- 15.10 Laurus Labs Ltd.
- Laurus Labs Ltd. - Overview
- Laurus Labs Ltd. - Product / Service
- Laurus Labs Ltd. - Key offerings
- SWOT
- 15.11 Lupin Ltd.
- Lupin Ltd. - Overview
- Lupin Ltd. - Business segments
- Lupin Ltd. - Key news
- Lupin Ltd. - Key offerings
- Lupin Ltd. - Segment focus
- SWOT
- 15.12 Macleods Pharmaceuticals Ltd.
- Macleods Pharmaceuticals Ltd. - Overview
- Macleods Pharmaceuticals Ltd. - Product / Service
- Macleods Pharmaceuticals Ltd. - Key offerings
- SWOT
- 15.13 MSN Laboratories
- MSN Laboratories - Overview
- MSN Laboratories - Product / Service
- MSN Laboratories - Key offerings
- SWOT
- 15.14 NATCO Pharma Ltd.
- NATCO Pharma Ltd. - Overview
- NATCO Pharma Ltd. - Product / Service
- NATCO Pharma Ltd. - Key offerings
- SWOT
- 15.15 Strides Pharma Ltd.
- Strides Pharma Ltd. - Overview
- Strides Pharma Ltd. - Product / Service
- Strides Pharma Ltd. - Key offerings
- SWOT
- 15.16 Teva Pharmaceutical Ltd.
- Teva Pharmaceutical Ltd. - Overview
- Teva Pharmaceutical Ltd. - Business segments
- Teva Pharmaceutical Ltd. - Key news
- Teva Pharmaceutical Ltd. - Key offerings
- Teva Pharmaceutical Ltd. - Segment focus
- SWOT
- 15.17 Viatris Inc.
- Viatris Inc. - Overview
- Viatris Inc. - Business segments
- Viatris Inc. - Key news
- Viatris Inc. - Key offerings
- Viatris Inc. - Segment focus
- SWOT
- 15.18 Zydus Group
- Zydus Group - Overview
- Zydus Group - Product / Service
- Zydus Group - Key offerings
- SWOT
16 Appendix
- 16 Appendix
- 16.1 Scope of the report
- Market definition
- Objectives
- Notes and caveats
- 16.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
- 16.3 Currency conversion rates for US$
- Currency conversion rates for US$
- 16.4 Research methodology
- 16.5 Data procurement
- 16.6 Data validation
- 16.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
- 16.8 Data synthesis
- 16.9 360 degree market analysis
- 360 degree market analysis
- 16.10 List of abbreviations
INFORMATION SOURCES
DATA ANALYSIS
REPORT WRITING
Get the report (PDF) sent to your email within minutes.
Complimentary full Excel data with your report purchase.
